Notice of Special Interest (NOSI): Improving Outcomes for Disorders of Human Communication
Notice Number:
NOT-DC-20-007

Key Dates

Release Date:
May 22, 2020
First Available Due Date:
June 16, 2020
Expiration Date:
January 10, 2022

Related Announcements

  • PA-18-334 -NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

  • PA-20-184 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required
  • PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

  • PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required

  • PAR-18-340 - NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 – Clinical Trial Required)
  • PA-19-272 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-19-270 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
  • PA-19-273 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
  • PA-19-271 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

Issued by

National Institute on Deafness and Other Communication Disorders (NIDCD)

Purpose

The purpose of this Notice of Special Interest (NOSI) is to improve health outcomes for individuals with deafness or communication disorders through effectiveness and health services research in the NIDCD mission areas of hearing, balance, smell, taste, voice, speech and language.

Background

One of the missions of the NIDCD is to improve the health outcomes for individuals with deafness or communication disorders. Scientifically-validated prevention, treatment, and rehabilitation approaches will lead to better personal and public health only if they are translated effectively from the research laboratory into routine practice. Efficacy studies measure how well a treatment or intervention works in a clinical trial or laboratory setting. Following efficacy studies, effectiveness studies further evaluate how an intervention performs in the complex and variable context of real-world practice, in various community, clinical and provider settings, and with a broad and diverse patient population. Substantial fall-off in effect sizes is often seen in the translation from efficacy to effectiveness research, highlighting the importance of this stage of evaluation. Health services research examines the impact of organization, financing and management of health care services on the delivery, quality, cost, access to and outcomes of such services, including demographic, social, economic, and health system factors as they relate to providing preventive, screening, diagnostic, treatment and rehabilitative services. This NOSI seeks to encourage effectiveness and health services research for improved outcomes in the prevention and treatment of disorders of hearing, balance, smell, taste, voice, speech and language.

Purpose and Research Objectives

NIDCD effectiveness research seeks to measure, evaluate and/or improve patient-centered outcomes following intervention for communication disorders. Effectiveness research seeks to determine to what degree an intervention works in patients/populations in general, real-world settings, such as in diverse populations and diverse provider and clinical practice settings. Research outcomes are usually broader in range than typical patient-oriented research studies and include an expanded assessment of outcomes compared to traditional clinical research metrics. For example, an outcomes study would measure functional status, well-being, quality of life, cost, health care resource use, etc., (as opposed to/or in conjunction with traditional clinical metrics such as measures of language, or speech discrimination in noise). Effectiveness research typically employs broader inclusion criteria and has fewer restrictions for participation than traditional clinical study/clinical trial/efficacy research performed under a tightly controlled research setting. Effectiveness research addresses patient-centered outcomes in practice-relevant environments, focuses on quality of life, patient experience of and satisfaction with health care, and the social and economic consequences of care. It may include evaluation of economic impacts linked to health outcomes, and may be performed at either the patient or population level, or both.

Health Services Research examines the impact of the organization, financing, and management of health care services on the delivery, quality, cost, access to and outcomes of such services, including demographic, social, economic, and health system factors as they relate to providing preventive, screening, diagnostic, treatment and rehabilitative services and patient outcomes of care. Research may focus on any/all of the different factors that impact access, utilization, and quality as related to outcomes of health care services. Variations in care (e.g., ethnic, cultural, provider, geographic based) are also considered. The structure, processes, and outcomes of health services are evaluated in order to determine the degree to which individuals receiving health care services actually experience measurable benefits. (http://www.hsrd.research.va.gov/funding/what-is-hsr.cfm)

Dissemination and Implementation Research seeks to understand how health information and scientifically based clinical practices are/are not adopted in a variety of settings. This includes research on health promotion and approaches to increase use of evidence-based guidelines by both individuals and health care providers. These studies focus on implementing research findings into practice. Individuals interested in applying for research support in Implementation and Dissemination Research should apply under the NIDCD-participating FOA PAR-19-274 "Dissemination and Implementation Research in Health (R01)" .

There is substantial overlap among the above-mentioned research areas and all require collaborative multidisciplinary investigations. Applicants are encouraged to create collaborative teams which may include clinical experts not only in the traditional NIDCD mission areas, but also in other medical specialties and health care professions as well as experts in sociology, health services, health outcomes, economics, biostatistics, public health, health care financing and organization, survey research, psychometrics, epidemiology, and evaluation.

Application and Submission Information

This notice applies to due dates on or after June 16, 2020 and subsequent receipt dates through January 10 2022.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PA-18-334 -NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

  • PA-20-184 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required
  • PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

  • PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required

  • PAR-18-340 - NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 – Clinical Trial Required)
  • PA-19-272 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-19-270 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
  • PA-19-273 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
  • PA-19-271 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-DC-20-007” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative. For due dates after May 25, 2020, applicants must use "FORMS-F".
Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.

Scientific/Research Contact(s)

Kelly King, Au.D, Ph.D.
NIDCD/Division of Scientific Programs
Telephone: 301-402-3458
Email: kingke@nidcd.nih.gov

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Christopher Myers
NIDCD/Division of Extramural Activities
Telephone: 301-402-0909
Email: myersc@mail.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices